Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.61 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.59 |
| ▸ | SUV39H2 | Q9H5I1 | 6/20 | 0.50 |
| ▸ | BTK | Q06187 | 2/20 | 0.49 |
| ▸ | AURKA | O14965 | 3/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.47 |
| ▸ | CKS1B | P61024 | 1/20 | 0.47 |
| ▸ | SKP1 | P63208 | 1/20 | 0.47 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29689781 | 0.89 | PDE10A (0.58) | MAP4K4PDE10ASUV39H2CKS1BSKP1 | |
| SCHEMBL22499904 | 0.89 | PDE10A (0.58) | MAP4K4PDE10ASUV39H2CKS1BSKP1 | |
| SCHEMBL5873711 | 0.85 | PDE10A (0.55) | MAP4K4PDE10ASUV39H2 | |
| SCHEMBL24166014 | 0.84 | MAP4K4 (0.59) | MAP4K4PDE10ASUV39H2BTKCKS1B | |
| SCHEMBL2142039 | 0.83 | MAP4K4 (0.62) | MAP4K4PDE10ASUV39H2BTKAURKA | |
| SCHEMBL110191 | 0.83 | MAP4K4 (0.62) | MAP4K4PDE10ASUV39H2BTKAURKA | |
| SCHEMBL2142278 | 0.83 | MAP4K4 (0.62) | MAP4K4PDE10ASUV39H2BTKAURKA | |
| SCHEMBL28601499 | 0.82 | SYK (0.57) | MAP4K4PDE10ASUV39H2CKS1BSKP1 | |
| SCHEMBL28601501 | 0.82 | SYK (0.57) | MAP4K4PDE10ASUV39H2CKS1BSKP1 | |
| SCHEMBL529863 | 0.82 | MAP4K4 (0.58) | MAP4K4PDE10ASUV39H2BTKAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7084156-B2 | 2-Aminoquinoline compounds | MERCK & CO., INC. (US) | 2006-08-01 | — | — | US | disclosed |
| US-20050026915-A1 | 2-Aminoquinoline compounds | MERCK SHARP & DOHME CORP. | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026915-A1 | 2-Aminoquinoline compounds | MCHR1, MCHR2, MC5R | MAP4K4 1963/4885PDE10A 1245/4885SUV39H2 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.